Previous close | 112.04 |
Open | 113.92 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 113.36 - 113.92 |
52-week range | 97.31 - 122.66 |
Volume | |
Avg. volume | 5,130 |
Market cap | 61.008B |
Beta (5Y monthly) | 0.33 |
PE ratio (TTM) | 65.91 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.44 (1.27%) |
Ex-dividend date | 18 Apr 2024 |
1y target est | N/A |
AstraZeneca has suffered an investor backlash over a £19m pay award for its chief executive, in a vote that will deepen concerns of an exodus of UK companies to the US.
Shell's CEO has expressed dissatisfaction with the London Stock Exchange's valuation, indicating the possibility of exploring other options, including the abandonment of its London listing.
"If we work through the sprint, and we are doing what we are doing, and we still don't see that the gap is closing, we have to look at all options," Bloomberg Opinion cited Chief Executive Officer Wael Sawan as saying. A spokesperson for Shell said Sawan had made comments along similar lines on several public occasions, adding that the company will "explore other options", if there was a valuation gap beyond 2025.